Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vennarecci, Giovanni
NCT06341764: Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma	Recruiting	2	38	Europe	Durvalumab 1120 mg, Durvalumab 1500 mg, Tremelimumab i.v. at 300 mg, Cisplatin (CDDP) 25 mg/mq i.v, Gemcitabine (GEM) 1000 mg/mq i.v.	National Cancer Institute, Naples	Cholangiocarcinoma	09/25	09/25